ImageneBio, Inc. (IMA)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-10) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | — | ||
| 10-Q | Q1-2025 | — | ||
| 10-K | FY-2024 | — | ||
| 10-Q | Q3-2024 | — | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | — | ||
| 10-K | FY-2023 | 8-K (2024-01-18) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) | — |
|
| Condensed Consolidated Statements of Stockholders' Equity (unaudited) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss (P) | ||
| Consolidated Statements of Redeemable Convertible Preferred Shares and Stockholders' Equity (deficit) | ||
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity | — |
|
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (P) | — |
|
| Condensed Consolidated Statements of Stockholders' Equity (P) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (P) | — |
|
| Consolidated Statements of Redeemable Convertible Preferred Shares and Stockholders' Equity (deficit) (P) | ||
| Notes | ||
| Accrued Expenses and Other Current Liabilities | ||
| Acquisition of Pionyr | — |
|
| Acquisition of Pionyr Therapeutics | — |
|
| Asset Sale and License Agreement | — |
|
| Asset Sales | — |
|
| Balance Sheet Components | ||
| Collaboration Agreement and Stock Purchase Agreement With Bristol Myers Squibb | ||
| Collaborative Arrangements and Licensing Agreements | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Employee Benefit Plan | — |
|
| Fair Value Measurements | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Lease Obligations | — |
|
| Leases | — |
|
| Marketable Securities | ||
| Merger Agreement and Loan and Security Agreement | ||
| Nature of Business and Basis of Presentation | ||
| Nature of Business and Organization | — |
|
| Net Loss Per Share | ||
| Net Loss Per Share Attributable To Common Stockholders | ||
| Organization | ||
| Organization and Basis of Presentation | — |
|
| Pay Vs Performance Disclosure | ||
| Preferred Shares | ||
| Prepaid Expenses and Other Current Assets | ||
| Property and Equipment, Net | ||
| Redeemable Convertible Preferred Stock and Stockholders' Equity | — |
|
| Related Party | — |
|
| Related Party Promissory Note Receivable and Cvr Liability | — |
|
| Related Party Transactions | ||
| Research License Agreements | ||
| Restructuring and Other Charges | ||
| Reverse Recapitalization | ||
| Segment Information | ||
| Stock-based Compensation | ||
| Stockholder's Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Term Loan Advances | ||